Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer

Keyphrases

• Phase II Trial 100%
• Interferon alpha-2b 100%
• Biliary Tract Cancer 100%
• 5-fluorouracil (5-FU) 66%
• Recombinant Human 66%
• Mucositis 66%
• Biliary Tree 66%
• Gallbladder Cancer 66%
• Treatment Cycle 66%
• Diarrhea 33%
• Chemotherapy 33%
• Adjuvant Therapy 33%
• Radiotherapy 33%
• Liver Transplantation 33%
• Disease Progression 33%
• Disease Status 33%
• Toxic Effects 33%
• Continuous Infusion 33%
• Complete Response 33%
• Subcutaneous Injection 33%
• Cholecystectomy 33%
• Median Time 33%
• Dermatitis 33%
• Partial Response 33%
• Median Survival Time 33%
• Venous Catheter 33%
• Decompression 33%
• Previously Untreated Patients 33%
• Prior Treatment 33%
• Fluorouracil 33%
• Granulocytopenia 33%
• Liver Resection 33%
• Asthenia 33%
• Drug Tolerance 33%
• Cholangiocarcinoma 33%

Medicine and Dentistry

• Phase II Trials 100%
• Interferon Alfa 2b 100%
• Biliary Tract Cancer 100%
• Gallbladder Carcinoma 66%
• Human Interferon 66%
• Mucositis 66%
• Malignant Neoplasm 33%
• Diarrhea 33%
• Adjuvant Therapy 33%
• Disease Exacerbation 33%
• Subcutaneous Injection 33%
• Liver Transplantation 33%
• Continuous Infusion 33%
• Cholecystectomy 33%
• Hepatectomy 33%
• Dermatitis 33%
• Median Survival Time 33%
• Fluorouracil 33%
• Cholangiocarcinoma 33%
• Granulocytopenia 33%
• Asthenia 33%
• Drug Tolerance 33%
• Diseases 33%
• Radiation Therapy 33%
• Chemotherapy 33%